The Current Ratio as of November 2024 (TTM) for BridgeBio Pharma, Inc. (BBIO) is 3.19

According to BridgeBio Pharma, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 3.19. This represents a change of -23.22% compared to the average of 4.16 of the last 4 quarters.

BridgeBio Pharma, Inc. (BBIO) Historical Current Ratio (quarterly & annually)

How has BBIO Current Ratio performed in the past?

The mean historical Current Ratio of BridgeBio Pharma, Inc. over the last ten years is 8.22. The current 3.19 Current Ratio has changed 3.79% with respect to the historical average. Over the past ten years (40 quarters), BBIO's Current Ratio was at its highest in in the March 2020 quarter at 15.19. The Current Ratio was at its lowest in in the March 2018 quarter at 0.

BridgeBio Pharma, Inc. (BBIO) Current Ratio by Quarter and Year

Discovering the peaks and valleys of BridgeBio Pharma, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

BridgeBio Pharma, Inc. (BBIO) Average Current Ratio

How has BBIO Current Ratio performed in the past?

The current Current Ratio of BridgeBio Pharma, Inc. (BBIO) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

BridgeBio Pharma, Inc. (BBIO) Current Ratio vs. Peers

How is BBIO’s Current Ratio compared to its peers?

BridgeBio Pharma, Inc.’s Current Ratio is less than IVERIC bio, Inc. (18.63), less than Blueprint Medicines Corporation (3.32), less than Amylyx Pharmaceuticals, Inc. (4.55), less than Karuna Therapeutics, Inc. (19.31), less than Day One Biopharmaceuticals, Inc. (14.62), less than Mirati Therapeutics, Inc. (7.54), less than Terns Pharmaceuticals, Inc. (32.99), less than Apellis Pharmaceuticals, Inc. (4.36), less than Cerevel Therapeutics Holdings, Inc. (10.22), greater than PTC Therapeutics, Inc. (2.10), less than Krystal Biotech, Inc. (7.97), less than Intercept Pharmaceuticals, Inc. (4.22), less than Madrigal Pharmaceuticals, Inc. (5.98), less than Acumen Pharmaceuticals, Inc. (10.43), less than Inozyme Pharma, Inc. (7.68), less than X4 Pharmaceuticals, Inc. (4.89),

Build a custom stock screener for BridgeBio Pharma, Inc. (BBIO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BridgeBio Pharma, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

BridgeBio Pharma, Inc. (BBIO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like BridgeBio Pharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.